Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) on second line (2L) treatment: An ad hoc analysis from POLARIX study Meeting Abstract
| Authors: | Oellerich, T.; Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; Ho, R.; Hirata, J.; Lee, C.; Masaquel, A.; Launonen, A. |
| Abstract Title: | Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) on second line (2L) treatment: An ad hoc analysis from POLARIX study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 267 |
| Language: | English |
| ACCESSION: | WOS:001091456900599 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: P759 -- Source: Wos |
